PT  - JOURNAL ARTICLE
AU  - Thoen, Anoushka
AU  - Steyaert, Jean
AU  - Alaerts, Kaat
AU  - Van Damme, Tine
TI  - Evaluating the potential of respiratory-sinus-arrhythmia biofeedback for reducing physiological stress in adolescents with autism: a protocol for a randomized controlled study
AID  - 10.1101/2021.02.27.21252570
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.27.21252570
4099  - http://medrxiv.org/content/early/2021/03/01/2021.02.27.21252570.short
4100  - http://medrxiv.org/content/early/2021/03/01/2021.02.27.21252570.full
AB  - Background Prior evidence points towards lower cardiac vagal modulation in individuals with Autism Spectrum Disorder (ASD) as compared to control groups. A cross-sectional phase in this study will gather more evidence concerning this topic. A longitudinal phase will explore the efficacy of a biofeedback intervention based on Respiratory Sinus Arrhythmia (RSA) in adolescents with ASD. Finally, a feasibility study will focus on a non-supervised RSA biofeedback intervention in this population.Methods The cross-sectional phase includes the comparison of adolescents with ASD (n=38) and age and gender matched typically developing peers. A standardized assessment will be used which contains physiological, cortisol and behavioral measurements. The longitudinal phase contains a randomized, single-blinded and sham-controlled design to determine the efficacy of supervised RSA biofeedback in adolescents with ASD (n=128). A follow-up phase of 5 weeks is included to evaluate the presence of retention effects. During the latter, a feasibility study will focus on a non-supervised intervention (n=62). Assessments as described previously are scheduled after the intervention and the follow-up phase.Discussion First, more conclusive evidence will be provided for the presence of lower cardiac vagal modulation in adolescents with ASD as well as the association between these lower values and physiological and behavioral indices. Second, the supervised intervention in adolescents with ASD is hypothesized to upregulate this cardiac vagal modulation and positively change behavioral and physiological parameters. Third, evidence regarding the feasibility and acceptability of a non-supervised intervention may open novel avenues for home-based interventions in this population.Study registration ClinicalTrials.gov, NCT04628715. Registered on 13 November 2020.Funding Funding is provided by the Marguerite-Marie Delacroix foundation with grant number GV/B-363. The funder will not have any role in any part of this study.Competing interests The authors declare that they have no conflict of interest.Availability of data and material All data from the participants will be de-identified and provided with a unique code. The coded data will be stored for 20 years in secured databases of the Research Group for Adapted Physical Activity and Psychomotor Rehabilitation, protected by the KU Leuven and will only be accessible by researchers of collaborating labs. The key to the coded data will be stored securely and confidentially in a separate electronic file. The saliva samples will be stored under appropriate conditions during the study at the biobank of the KU Leuven and will be destroyed afterwards. Participants waive any intellectual property rights on findings that might result from the analysis of their saliva samples.Code availability Not applicable.Author’s contributions All authors contributed to the writing of this manuscript and the grant proposal. Anoushka Thoen leads the study and data management under supervision of Tine Van Damme, who provided facilities and equipment. All authors read and approved the final manuscript.Ethics approval Ethical approval for this study was granted by both the Ethics Committee UPC KU Leuven on July 2nd 2020 (ref. EC2020-541, version 2.0) and the Ethics Committee Research UZ/KU Leuven on October 20th 2020 (ref: S64219, version 1.0).Consent to participate Parents of the participants should provide informed consent in addition to the informed assent provided by the participants themselves. Participants may withdraw consent and participation at any time. The participant’s request to withdraw from the study will always be respected and reasons to withdraw are not obliged to be mentioned. The sponsor of this study is KU Leuven (Oude Markt 13, 3000 Leuven, Belgium) and will have no role in any part of this study.Consent for publication Authorship to publications will be determined in accordance with the requirements published by the International Committee of Medical Journal Editors and in accordance with the requirements of the respective peer-reviewed medical journal.Amendments Every substantial adjustment to the protocol will be communicated to the Ethics Committee UPC KU Leuven and the Ethics Committee Research UZ/KU Leuven as an amendment to the protocol. Only after approval of this amendment, the adjustments can be implemented and communicated to the researchers and participants.Auditing The researchers will permit study-related monitoring, audits, Ethical Committee review and regulatory inspection, providing direct access to all related source data/documents.Dissemination of study results The results of this study will be used for publication in peer-reviewed journals. There will also be a general dissemination of the study results for the participants and personal results will be provided upon request.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04628715Funding StatementThe research reported is supported by funding from the Marguerite Marie Delacroix Foundation (awarded to AT).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was granted by both the Ethics Committee UPC KU Leuven on July 2nd 2020 (ref. EC2020-541, version 2.0) and the Ethics Committee Research UZ/KU Leuven on October 20th 2020 (ref: S64219, version 1.0).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a protocol paper thus no data is available.ASDAutism Spectrum DisorderAQAutism QuotientDASSDepression Anxiety and Stress ScalesDSM-IV/VDiagnostics and Statistical Manual of mental disordersECGElectrocardiogramFUFollow-upHF-HRVHigh Frequency Heart Rate VariabilityHRVHeart Rate VariabilityPAVSPhysical Activity Vital SignPSSPerceived Stress ScaleRBS-RRepetitive Behavior Scale – RevisedRMSSDRoot Mean Square of Successive DifferencesRSARespiratory Sinus ArrhythmiaSDQStrengths and Difficulties QuestionnaireSRSSocial Responsiveness ScaleSSRTSocial Stress Recall TaskTDTypically DevelopingVASVisual Analogue Scale.